Innate Pharma Stock Market Value
| IPHA Stock | USD 1.69 0.02 1.20% |
| Symbol | Innate |
Innate Pharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.44) | Revenue Per Share | Quarterly Revenue Growth (0.69) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Innate Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Innate Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Innate Pharma.
| 12/20/2024 |
| 01/19/2025 |
If you would invest 0.00 in Innate Pharma on December 20, 2024 and sell it all today you would earn a total of 0.00 from holding Innate Pharma or generate 0.0% return on investment in Innate Pharma over 30 days. Innate Pharma is related to or competes with HCW Biologics, Inhibrx, Anebulo Pharmaceuticals, Shattuck Labs, Champions Oncology, Century Therapeutics, and Addex Therapeutics. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the trea... More
Innate Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Innate Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Innate Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.05 | |||
| Information Ratio | 0.0262 | |||
| Maximum Drawdown | 116.36 | |||
| Value At Risk | (11.04) | |||
| Potential Upside | 13.42 |
Innate Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innate Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Innate Pharma's standard deviation. In reality, there are many statistical measures that can use Innate Pharma historical prices to predict the future Innate Pharma's volatility.| Risk Adjusted Performance | 0.0331 | |||
| Jensen Alpha | 0.3689 | |||
| Total Risk Alpha | 0.0558 | |||
| Sortino Ratio | 0.0506 | |||
| Treynor Ratio | 0.9479 |
Innate Pharma Backtested Returns
Innate Pharma appears to be extremely dangerous, given 3 months investment horizon. Innate Pharma holds Efficiency (Sharpe) Ratio of 0.0348, which attests that the entity had a 0.0348% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Innate Pharma, which you can use to evaluate the volatility of the firm. Please utilize Innate Pharma's Risk Adjusted Performance of 0.0331, downside deviation of 7.05, and Market Risk Adjusted Performance of 0.9579 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Innate Pharma holds a performance score of 2. The company retains a Market Volatility (i.e., Beta) of 0.4, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Innate Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Innate Pharma is expected to be smaller as well. Please check Innate Pharma's total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Innate Pharma's current trending patterns will revert.
Auto-correlation | 0.85 |
Very good predictability
Innate Pharma has very good predictability. Overlapping area represents the amount of predictability between Innate Pharma time series from 20th of December 2024 to 4th of January 2025 and 4th of January 2025 to 19th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Innate Pharma price movement. The serial correlation of 0.85 indicates that around 85.0% of current Innate Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.85 | |
| Spearman Rank Test | 0.6 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Innate Pharma lagged returns against current returns
Autocorrelation, which is Innate Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Innate Pharma's stock expected returns. We can calculate the autocorrelation of Innate Pharma returns to help us make a trade decision. For example, suppose you find that Innate Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Innate Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Innate Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Innate Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Innate Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
Innate Pharma Lagged Returns
When evaluating Innate Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Innate Pharma stock have on its future price. Innate Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Innate Pharma autocorrelation shows the relationship between Innate Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in Innate Pharma.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Innate Pharma Correlation, Innate Pharma Volatility and Innate Pharma Alpha and Beta module to complement your research on Innate Pharma. For information on how to trade Innate Stock refer to our How to Trade Innate Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Innate Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.